Head-to-head evidence
exendin-4 Fc fusion (JY09) vs IcoSema
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
exendin-4 Fc fusion (JY09)
Developed by Beijing Dongfang Biotech
NCT06247748 · Phase 1 · completed
Every participant received the same open-label treatment with no control group, and the study measured drug-interaction and pharmacokinetic markers rather than a clinical benefit. No results have been posted.
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exendin-4 Fc fusion (JY09)'s landscape · IcoSema's landscape